DrugPatentWatch Database Preview

Encorafenib - Generic Drug Details

See Plans and Pricing

« Back to Dashboard

What are the generic sources for encorafenib and what is the scope of freedom to operate?

Encorafenib is the generic ingredient in one branded drug marketed by Array Biopharma Inc and is included in one NDA. There are eleven patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Encorafenib has one hundred and thirty patent family members in forty-nine countries.

One supplier is listed for this compound.

Summary for encorafenib

International Patents:	130
US Patents:	11
Tradenames:	1
Applicants:	1
NDAs:	1
Suppliers / Packagers:	1
Bulk Api Vendors:	37
Clinical Trials:	22
Patent Applications:	78
DailyMed Link:	encorafenib at DailyMed

Recent Clinical Trials for encorafenib

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
ECOG-ACRIN Cancer Research Group	Phase 2
Bristol-Myers Squibb (BMS)	Phase 1/Phase 2
EADO - European Association of Dermato Oncology	Phase 2

See all encorafenib clinical trials

Synonyms for encorafenib

1269440-17-6

8L7891MRB6

A13226

AC-30230

AS-35201

BCP08458

BDBM221688

Braftovi

Braftovi (TN)

Carbamic acid, N-[(1S)-2-[[4-[3-[5-chloro-2-fluoro-3-[(methylsulfonyl)amino]phenyl]-1-(1-methylethyl)-1H-pyrazol-4-yl]-2-pyrimidinyl]amino]-1-methylethyl]-, methyl ester

CHEMBL3301612

CMJCXYNUCSMDBY-ZDUSSCGKSA-N

CS-2289

D11053

DB11718

DTXSID00155347

Encorafenib (JAN/USAN/INN)

Encorafenib (LGX818)

Encorafenib [USAN:INN]

EX-A1587

GTPL7908

HY-15605

LGX 818

LGX-818

LGX-818(Encorafenib)

LGX818

Methyl N-[(2S)-1-({4-[3-(5-chloro-2-fluoro-3-methanesulfonamidophenyl)-1-(propan-2-yl)-1H-pyrazol-4-yl]pyrimidin-2-yl}amino)propan-2-yl]carbamate

methyl N-[(2S)-1-[[4-[3-[5-chloro-2-fluoro-3-(methanesulfonamido)phenyl]-1-propan-2-ylpyrazol-4-yl]pyrimidin-2-yl]amino]propan-2-yl]carbamate

MFCD25976758

NCGC00378599-03

NVP-LGX818

NVP-LGX818-NXA

s7108

SB16926

SCHEMBL8228295

UNII-8L7891MRB6

US9314464, 9

ZINC68249103

US Patents and Regulatory Information for encorafenib

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Array Biopharma Inc	BRAFTOVI	encorafenib	CAPSULE;ORAL	210496-001	Jun 27, 2018		DISCN	Yes	No
Array Biopharma Inc	BRAFTOVI	encorafenib	CAPSULE;ORAL	210496-002	Jun 27, 2018		RX	Yes	Yes
Array Biopharma Inc	BRAFTOVI	encorafenib	CAPSULE;ORAL	210496-002	Jun 27, 2018		RX	Yes	Yes
Array Biopharma Inc	BRAFTOVI	encorafenib	CAPSULE;ORAL	210496-001	Jun 27, 2018		DISCN	Yes	No
Array Biopharma Inc	BRAFTOVI	encorafenib	CAPSULE;ORAL	210496-001	Jun 27, 2018		DISCN	Yes	No			Y	Y
Array Biopharma Inc	BRAFTOVI	encorafenib	CAPSULE;ORAL	210496-002	Jun 27, 2018		RX	Yes	Yes

International Patents for encorafenib

Country	Patent Number	Estimated Expiration
India	2469DEN2012
Portugal	2727918
Croatia	P20120577
Japan	5475888
Chile	2014001337
Singapore	11201401260Q

Supplementary Protection Certificates for encorafenib

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2727918	300975	Netherlands		PRODUCT NAME: COMBINATIE VAN BINIMETINIB EN ENCORAFENIB, BEIDE IN ALLE VORMEN ZOALS BESCHERMD DOOR HET BASISOCTROOI; REGISTRATION NO/DATE: EU/1/18/1314 20180924
2727918	CA 2019 00013	Denmark		PRODUCT NAME: KOMBINATION AF BINIMETINIB OG ENCORAFENIB, I ALLE FORMER HVERT ISAER BESKYTTET AF GRUNDPATENTET; REG. NO/DATE: EU/1/18/1315 ELLER EU/1/18/1314 20180924
2727918	2019C/509	Belgium		PRODUCT NAME: COMBINAISON DE BINIMETINIB ET D'ENCORAFENIB, CHACUN SOUS TOUTES LES FORMES PROTEGEES PAR LE BREVET DE BASE; AUTHORISATION NUMBER AND DATE: EU/1/18/1315 ET EU/1/18/1314 20180924
2727918	122019000023	Germany
2470526	PA2019005	Lithuania		PRODUCT NAME: ENKORAFENIBAS BET KOKIOMIS FORMOMIS, KURIOMS TAIKOMA PAGRINDINIO PATENTO APSAUGA; REGISTRATION NO/DATE: EU/1/18/1314 20180920
2470526	C20190011 00282	Estonia		PRODUCT NAME: ENKORAFENIIB;REG NO/DATE: EU/1/18/1314 24.09.2018